Natus Medical (BABY) Downgraded by ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Natus Medical (NASDAQ:BABY) from a hold rating to a sell rating in a research note issued to investors on Saturday.

BABY has been the subject of a number of other reports. BidaskClub lowered Natus Medical from a buy rating to a hold rating in a report on Friday, September 7th. Zacks Investment Research lowered Natus Medical from a hold rating to a sell rating in a report on Friday, July 27th. Finally, Roth Capital set a $36.00 price objective on Natus Medical and gave the stock a buy rating in a report on Thursday, October 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of $42.50.

Shares of Natus Medical stock opened at $29.86 on Friday. Natus Medical has a one year low of $27.69 and a one year high of $41.55. The stock has a market capitalization of $1.01 billion, a P/E ratio of 20.60 and a beta of 0.54. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.21 and a quick ratio of 2.31.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.02). The firm had revenue of $130.60 million during the quarter, compared to the consensus estimate of $132.92 million. Natus Medical had a negative net margin of 3.53% and a positive return on equity of 11.34%. The business’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.40 earnings per share. Analysts expect that Natus Medical will post 1.48 EPS for the current fiscal year.

In other Natus Medical news, insider Jonathan Kennedy sold 47,600 shares of the business’s stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $36.85, for a total transaction of $1,754,060.00. Following the completion of the sale, the insider now directly owns 161,628 shares of the company’s stock, valued at approximately $5,955,991.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rutabaga Capital Management LLC MA purchased a new position in shares of Natus Medical in the 3rd quarter worth approximately $9,272,000. Polaris Capital Management LLC boosted its stake in shares of Natus Medical by 19.9% in the 3rd quarter. Polaris Capital Management LLC now owns 79,420 shares of the medical equipment provider’s stock worth $2,831,000 after buying an additional 13,200 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Natus Medical by 4.6% in the 3rd quarter. BlackRock Inc. now owns 5,013,693 shares of the medical equipment provider’s stock worth $178,739,000 after buying an additional 220,521 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Natus Medical by 14.6% in the 3rd quarter. Janus Henderson Group PLC now owns 3,111,761 shares of the medical equipment provider’s stock worth $110,934,000 after buying an additional 396,772 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Natus Medical by 7.6% in the 3rd quarter. Alliancebernstein L.P. now owns 55,486 shares of the medical equipment provider’s stock worth $1,978,000 after buying an additional 3,930 shares during the last quarter. Hedge funds and other institutional investors own 95.86% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Story: What Does Beta Mean In Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply